Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: influenza virus vaccines - Vaxart

Next Previous
Drug Profile

Research programme: influenza virus vaccines - Vaxart

Alternative Names: Avian influenza quadrivalent vaccine - Vaxart; Bird flu quadrivalent vaccine - Vaxart; H1N1 swine influenza vaccine - Vaxart; H3N2 seasonal influenza vaccine - Vaxart; H5N1 avian influenza virus quadrivalent vaccine - Vaxart; H7N9 avian influenza vaccine - Vaxart; Oral adenovirus-based quadrivalent avian flu influenza vaccine - Vaxart; Oral quadrivalent seasonal influenza vaccine - Vaxart; Pandemic H5N1 influenza A virus quadrivalent vaccine - Vaxart

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxart
  • Class Influenza virus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H3N2 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
  • Discontinued Influenza A virus H1N1 subtype

Most Recent Events

  • 28 May 2023 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (PO, Tablet)
  • 24 Feb 2021 Vaxart files for patent protection for proprietary technology, VAAST™ platform, and creations for oral vaccination using adenovirus and TLR3 agonists in USA and other countries
  • 13 Apr 2019 Pharmacodynamics data from a preclinical study in Influenza A virus H5N1 subtype presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top